Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)

Bortezomib and Temozolomide in Recurrent GlioblastomaGrade-4 WithGlioma Unmethylated MGMT Promoter (BORTEM-17)

[...] rable recurrent tumor Tumor not available for radio-surgery If previously treated with gammaknife, at least one evaluable lesion outside the irradiated area is required, unless the time after the radiosurgery is 12 weeks or more Written informed consent for study participation and tumour, [...] y study related procedure. Karnofsky performance status ≥ 70% WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/ [...] dium > 130 mmol/L Serum potassium level within normal limit Stable or reduced doses of corticosteroids for at least 1 week prior to enrolment Negative pregnancy test no longer than 14 days p [...] [...]

[...] eparin allowed Stable or decreasing steroid dose during the twolast weeksweek before study entry Patients previously treated with neurosu [...] neuropathy ≥ grade 2 Previous treatment with bevacizumab or PCVlomustine alone or as a combination therapy for ralapsed glioblastoma (PCV as primary treatment of low grade glioma, before development of glioblastoma, is allowed) Myocardial infarction within the past 6 months [...] nal drugs must be stopped at least 12 weeks prior to therapy or treatment failure under other experimental therapy must be confirmed before study entry. If progression during other experim [...] [...]